Triclopyr |
| Catalog No.GD21761 |
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 55335-06-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Triclopyr (3 mM; 48 hours) treatment exhibits cytotoxicity against N2a cells[1].
Pharmacokinetic Analysis
Triclopyr exhibits moderate half-lives (dog 25 h and monkey 6.3 h) due to plasma clearance (18 mL/h/kg, 26 mL/h/kg respectively) following oral gavage (3 male beagle dogs ;0.5 mg/kg, 5 mg/kg and 20 mg/kg) and intravenous administration (1 male rhesus monkey; 30 mg/kg) [2].
[1]. Tejaswini P Reddy, et al. Toxicity of neurons treated with herbicides and neuroprotection by mitochondria-targeted antioxidant SS31. Int J Environ Res Public Health. 2011 Jan;8(1):203-21.
[2]. C Timchalk, et al. Pharmacokinetics of triclopyr (3,5,6-trichloro-2-pyridinyloxyacetic acid) in the beagle dog and rhesus monkey: perspective on the reduced capacity of dogs to excrete this organic acid relative to the rat, monkey, and human. Toxicol Appl Pharmacol. 1997 Jun;144(2):268-78.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *